Catalog #CPB505
Bispecific anti-mouse PD-1 x anti-mouse CTLA4 - PREORDER
Clone
Derived from clones RMP1-14 and 9D9
Reactivities
Mouse
Isotype
mouse IgG2a (LALA-PG)-scFv, κ
Product Description
CPB505 is a 2+2 symmetric tetravalent bispecific checkpoint inhibitor antibody with the same structure as human therapeutic Cadonilimab but designed to target mouse programmed cell death protein‑1 (PD‑1, CD279) and mouse cytotoxic T‑lymphocyte–associated antigen‑4 (CTLA-4) for use in murine models. Like Cadonilimab, CPB505 has two PD‑1‑blocking and two CTLA‑4‑blocking paratopes to confer high avidity in context of high checkpoint density such as within the tumor microenvironment, and has an engineered null Fc-region through the incorporation of LALA-PG Fc-silencing mutations to eliminating or greatly reduce binding to Fcγ receptors and C1q, minimizing ADCC, ADCP, and complement activation against checkpoint‑expressing lymphocytes. The synergistic effect of Fc‑null engineering and tumor‑biased engagement are intended to reduce systemic immune‑related toxicities that are common with conventional PD‑1 plus CTLA‑4 combinations, while maintaining robust antitumor activity. Unlike Cadonilimab, CPB505 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models. This bispecific is designed to simultaneously bind mouse PD-1 and mouse CTLA-4 on T cells, particularly tumor‑infiltrating lymphocytes, to engage both checkpoints on the same or neighboring T cells and provide coordinated dual checkpoint blockade within the tumor microenvironment. Blocking PD‑1 prevents interaction with PD‑L1/PD‑L2 and reverses PD‑1–mediated inhibitory signaling, restoring T‑cell activation, proliferation, and effector function against tumor cells. Concurrent CTLA‑4 blockade reduces competition with CD28 for CD80/CD86, enhancing costimulatory signaling and promoting expansion and priming of effector T cells, further amplifying antitumor responses.
Specifications
| Isotype | mouse IgG2a (LALA-PG)-scFv, κ |
|---|---|
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | LALA-PG |
| Reported Applications |
ELISA For information on in-vivo applications, please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein G |
| Molecular Weight | 202.9 |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |